Clinical Trial Finder

Inclusion Criteria:

1. Histopathologically confirmed IDH wild type glioblastoma, first recurrence after standard chemoradiation; suitable for standard-of-care re-resection; 2. Age ≥ 18 years; 3. Able and willing to give written informed consent; 4. Life expectancy >3 months, allowing adequate follow-up of toxicity evaluation and antitumor activity; 5. KPS performance status ≥70.

Exclusion Criteria:

1. Currently actively treated in another antitumor clinical trial (excluding DRUP and STELLAR studies); 2. Patients with any other clinically significant medical condition which, in the opinion of the treating physician, makes it undesirable for the patient to participate in medication studies or which could jeopardize compliance with study requirements including, but not limited to ongoing or active infection, significant uncontrolled hypertension, or severe psychiatric illness/social situations.

Rationale: Glioblastoma (GBM), the most common primary brain tumor, is without exception lethal. Every year 1000 patients are diagnosed with this disease in the Netherlands. Despite neurosurgery, chemo -and radiation therapy, these tumors inevitably recur. Currently, there is no gold standard at time of recurrence and treatment options are limited. In a retrospective study in two Dutch neuro-oncology centers, the overall survival (OS) for patients with recurrent GBM receiving best supportive care was 3 months, while patients receiving systemic treatment (usually nitrosurea), radiation therapy or surgery followed by systemic treatment or radiotherapy had respectively 7.3 months, 9.2 months and 11 months OS. Unfortunately, the results of dedicated trials with new drugs have been very disappointing. For those to be meaningful, extensive molecular screening is needed. The goal of the project is to obtain the evidence for changing standard of care procedures to include extensive molecular diagnostics and consequently adapt care guidelines for this specific patient group with very poor prognosis by offering optimal and timely benefit from novel therapies, even in the absence of traditional registration trials for this small volume cancer indication. Objective: To determine the value of and generate the clinical evidence for routine application of Whole Genome Sequencing (WGS)-based diagnostics and targeted therapy guidance for glioblastoma patients at time of first recurrence. Study design: Prospective diagnostic multicenter cohort study Study population: Adult glioblastoma patients with recurrent disease that are undergoing resection or debulking as part of their standard care and from whom written informed consent is obtained. Intervention: A 10 mL blood sample will be drawn once to assess each patient's germline DNA background variation that will discriminate somatic mutations from the patient's germline DNA background variations. All other interventional procedures required to perform this study are part of standard procedures. Main study parameters/endpoints: Primary study endpoint: Overall survival. Secondary study endpoints: - Tumor and blood collection success rate (target >85% of all patients included) - Number of successful WGS reports (reports for >80% of patients for which tumor material was collected) - Number of targeted treatment options identified (at least one potentially actionable DNA alteration in >75% of patients with a WGS report) - Number of experimental treatments available for GBM patients (relevant (off-label) drugs for at least 50% of the identified indications should be available through a study, including the Drug Rediscovery Protocol (DRUP) - Thirty-two percent of patients starting a targeted treatment in presence of actionable variant (currently 16%)

Arms

Experimental: whole genome sequencing after standard of care resection at first relapse

Interventions

Diagnostic Test: - whole genome sequencing

whole genome sequencing will be performed on tumor material after re-resection per standard of care